Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol
Open Access
- 25 September 2019
- journal article
- Published by F1000 Research Ltd in HRB Open Research
Abstract
Background: The Myopia Outcome Study of Atropine in Children (MOSAIC) aims to explore the efficacy, safety, acceptability and mechanisms of action of 0.01% unpreserved atropine for myopia control in a European population. Methods: MOSAIC is an investigator-led, double-masked, placebo-controlled, randomised clinical trial (RCT) investigating the efficacy, safety and mechanisms of action of 0.01% atropine for managing progression of myopia. During Phase 1 of the trial, 250 children aged 6-16 years with progressive myopia instil eye drops once nightly in both eyes from randomisation to month 24. From month 24 to 36 participants are re-randomised in Phase 2 of the trial, into continued 0.01% atropine, and washout, at 1:1 ratio for those participants initially randomised to the intervention arm (n=167), during which any potential rebound effects on cessation of treatment will be monitored. All participants initially assigned to the placebo (n=83) crossover to the intervention arm of the study for Phase 2, and from month 24 to 36, instil 0.01% atropine eye drops in both eyes once nightly. Further treatment and monitoring beyond 36 months is planned (Phase 3) and will be designed dependent on the outcomes of Phase 1. Results: The primary outcome measure is cycloplegic spherical equivalent refractive error progression at 24 months. Secondary outcome measures include axial length change as well as the rebound, safety and acceptability profile of 0.01% atropine. Additional analyses will include the mechanisms of action of 0.01% atropine for myopia control. Conclusions: The generalisability of results from previous clinical trials investigating atropine for myopia control is limited by the predominantly Asian ethnicity of previous study populations. MOSAIC is the first RCT to explore the efficacy, safety and mechanisms of action of unpreserved 0.01% atropine in a predominantly White population.Funding Information
- Health Research Board (MRCG2016-13)
- Fighting Blindness (MRCG 2016-13)
This publication has 49 references indexed in Scilit:
- Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye dropsClinical Ophthalmology, 2013
- Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium systemBritish Journal of Ophthalmology, 2011
- Classification of iris colour: review and refinement of a classification schemaClinical & Experimental Ophthalmology, 2011
- Blocked Randomization with Randomly Selected Block SizesInternational Journal of Environmental Research and Public Health, 2010
- Evaluating the burden of amblyopia treatment from the parent and child’s perspectiveJournal of American Association for Pediatric Ophthalmology and Strabismus, 2010
- Trends in blind registration in the adult population of the Republic of Ireland 1996-2003British Journal of Ophthalmology, 2006
- Prevalence of blindness and low vision in an Italian population: a comparison with other European studiesEye, 2005
- Causes of visual impairment in people aged 75 years and older in Britain: an add-on study to the MRC Trial of Assessment and Management of Older People in the CommunityBritish Journal of Ophthalmology, 2004
- The Ethics of Social Research with Children: An Overview1Children & Society, 1996
- Interaction of drugs with ocular melanin in vitroExperimental Eye Research, 1980